Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390083 | 0.89 | PARP10 (0.46) | PNMTNOS3NOS2HRH1HRH4 | |
| SCHEMBL9336427 | 0.78 | PNMT (0.37) | ALDH1A1PNMTNOS3NOS2GAA | |
| SCHEMBL161158 | 0.76 | — | — | |
| SCHEMBL12483381 | 0.72 | NOS3 (0.41) | TSHRPNMTNOS3NOS2HRH1 | |
| SCHEMBL9923686 | 0.72 | — | — | |
| SCHEMBL631537 | 0.72 | MAOA (0.42) | TSHRALDH1A1PNMTNOS3NOS2 | |
| SCHEMBL8195075 | 0.72 | USP2 (0.42) | ALDH1A1NOS2OR51E2PDPK1PARP1 | |
| SCHEMBL504352 | 0.71 | GSK3B (0.40) | ALDH1A1CDK1MAPKAPK2HRH1HRH4 | |
| Hydrochloric Acid SCHEMBL30018400 | 0.71 | PNMT (0.41) | ALDH1A1PNMTOR51E2GAAKDM4E | |
| SCHEMBL21584043 | 0.69 | FABP6 (0.45) | TSHRALDH1A1NOS3NOS2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12157726-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | SHANGHAI ZHIMENG BIOPHARMA INC. | 2024-12-03 | — | — | US | disclosed |
| EP-3798220-B1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-3798220-B1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-20220227721-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2022-07-21 | — | — | US | disclosed |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2022-06-21 | — | — | US | disclosed |
| CN-110511220-B | P-diaminobenzene derivatives as potassium channel modulators, process for their preparation and their use in medicine | 上海挚盟医药科技有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20210163429-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2021-06-03 | — | — | US | disclosed |
| US-20210163429-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2021-06-03 | — | — | US | disclosed |
| EP-3798220-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | Shanghai Zhimeng Biopharma, Inc. (CN) | 2021-03-31 | — | — | EP | disclosed |
| US-5532240-A | ANTIPSYCHOTIC AGENTS AND ANTISEROTONIN AGENTS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
| US-5321021-A | Tricyclic pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 1994-06-14 | — | — | US | disclosed |
| EP-0596125-A1 | CONDENSED THIOPHENE COMPOUND AND PHARMACEUTICAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-05-11 | — | — | EP | disclosed |
| EP-0318682-B1 | TRICYCLIC THIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1993-03-31 | — | — | EP | disclosed |
| US-5036066-A | Muscle relaxants, anxiolytic agents, anticonvulsants | HOFFMANN-LA ROCHE INC. (US) | 1991-07-30 | — | — | US | disclosed |
| EP-0183994-B1 | TRICYCLIC PYRIDONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1990-03-21 | — | — | EP | disclosed |
| US-4889848-A | 4-OXO-4H-BENZO(A)QUINOLIZINES; MUSCLE RELAXANTS; SEDATIVES; ANTICONVULSANTS; ANXIOLYTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1989-12-26 | — | — | US | disclosed |
| EP-0318682-A2 | Tricyclic thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-06-07 | — | — | EP | disclosed |
| US-4735940-A | Tricyclic pyridine derivatives and pharmaceutical compositions | HOFFMANN-LA ROCHE INC. (US) | 1988-04-05 | — | — | US | disclosed |
| EP-0183994-A1 | Tricyclic pyridone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12157726-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | KCNJ2, KCNN2, KCNH2 | TSHR 1830/4885ALDH1A1 1733/4885CDK1 4214/4885 |
| US-20220227721-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | KCNJ2, KCNN2, KCNH2 | TSHR 1830/4885ALDH1A1 1733/4885CDK1 4214/4885 |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | KCNJ2, KCNN2, KCNH2 | TSHR 1799/4885ALDH1A1 1705/4885CDK1 4157/4885 |
| US-20210163429-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | KCNJ2, KCNN2, KCNH2 | TSHR 1799/4885ALDH1A1 1705/4885CDK1 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.